Gene Logic Garners NCI Contract for Preclinical Toxicology Studies

NEW YORK, April 8 (GenomeWeb News) - Gene Logic today said it has been tapped by the National Cancer Institute's Division of Cancer Treatment and Diagnosis to provide it with preclinical safety and pharmacology studies pertinent to its core cancer, AIDS, and AIDS-related illness research.

Terms of the deal call for Gene Logic to use its toxicogenomics platform to perform preclinical in vivo studies related to drug toxicity. The agreement, which is funded by NCI, the National Institutes of Health, and the Department of Health and Human Services, will pay Gene Logic up to $6.9 million over the next seven years.

This announcement follows several other government contracts awarded to Gene Logic over the last six months, including a multiyear contract with the National Institute of Allergy and Infectious Diseases, a one-year contract with the UniformedServicesUniversityof the Health Sciences, and an extension with the National Institute of Environmental Health Sciences.